Affinity Asset Advisors LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Affinity Asset Advisors LLC
CRD #312788
SEC #801-120744
CIK #0001773195
AUM 1,691.1 M (2026-03-27)
Employees 10 (70% Investors, 0% Brokers)
Phone646-481-3856
Address450 Park Avenue
New York, NY 10022
Source [IAPD] [EDGAR] [Website] [Twitter]
Total AUM ($M)
17001360102068034002010201520212027
In the News
Sat, 25 Jul 2026 Affinity Asset Advisors LLC Reduces Holdings in MBX Biosciences, Inc. $MBX — MarketBeat
Sat, 25 Jul 2026 Affinity Asset Advisors LLC Decreases Holdings in Jade Biosciences, Inc. $JBIO — MarketBeat
Sat, 25 Jul 2026 Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO — MarketBeat
Sat, 25 Jul 2026 Affinity Asset Advisors LLC Has $54.77 Million Position in Praxis Precision Medicines, Inc. $PRAX — MarketBeat
Sat, 25 Jul 2026 Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI — MarketBeat
Sector Form 13F Holdings Value ($M)
Apogee Therapeutics Inc 108.2
Xenon Pharmaceuticals Inc 97.4
Erasca Inc 86.6
Insmed Inc 78.5
Roivant Sciences Ltd 77.6
Aeglea Biotherapeutics Inc 64.5
Praxis Precision Medicines Inc 54.8
Anaptysbio Inc 52.1
Alkermes PLC 47.7
Cytokinetics Inc 46.2
View All
Holdings by Sector ($M)
20001600120080040002021202320252027
Type Form D Funds Date Sold AUM
VC Affinity Healthcare Special CT II LP [2022-03-28] 7.5 M 7.3 M
Filed 2022-01-10 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
HF Affinity Healthcare Fund LP [2021-03-09] 167.4 M 1,691.1 M
Filed 2025-09-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
VC Affinity Healthcare Special SG LP [2021-03-09] 2.2 M 3.5 M
Offered $2,155,000 · Filed 2020-08-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 2 1,691.1
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 2 1,691.1
By Discretionary
Discretionary 2 1,691.1
Non-Discretionary 0 0.0
Total 2 1,691.1
By Non-United States Persons
Non-United States Persons 392.1
United States Persons 1,299.0
Total 2 1,691.1
Form D Directors Role # Filings # Firms 2011 - 2026
Jonathan Chu Executive Officer 13 2
Andrew Weinstein Executive Officer 6 2
Michael Cho Executive Officer 6 2
Affinity Asset Advisors LLC Executive Officer, Promoter 4 2
Affinity Healthcare GP LLC Executive Officer 2 2
Affinity Healthcare Special GP II LLC Executive Officer 1 1
Affinity Healthcare Fund LP Promoter 1 1
Affinity Healthcare Special GP LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001773195]
SC 13G [0001773195]
Form 13D/13G Filer Form 13D/13G Subject Filed
Affinity Asset Advisors LLC Helix Acquisition Corp III [2026-05-14]
Affinity Asset Advisors LLC Forte Biosciences Inc [2025-12-23]
Affinity Asset Advisors LLC OVID Therapeutics Inc [2025-12-18]
Affinity Asset Advisors LLC Verrica Pharmaceuticals Inc [2025-12-03]
Affinity Asset Advisors LLC Sutro Biopharma Inc [2025-10-23]
Affinity Asset Advisors LLC Lexeo Therapeutics Inc [2025-06-04]
Affinity Asset Advisors LLC Ventyx Biosciences Inc [2025-05-30]
Affinity Asset Advisors LLC Karyopharm Therapeutics Inc [2025-04-10]
Affinity Asset Advisors LLC Avalo Therapeutics Inc [2024-12-31]
Affinity Asset Advisors LLC Inozyme Pharma Inc [2024-12-09]
Affinity Asset Advisors LLC NextCure Inc [2024-06-27]
Affinity Asset Advisors LLC Eliem Therapeutics Inc [2024-05-07]
Affinity Asset Advisors LLC Aeglea Biotherapeutics Inc [2023-07-03]
Affinity Asset Advisors LLC Context Therapeutics Inc [2022-05-09]
Affinity Asset Advisors LLC Vincerx Pharma Inc [2021-11-22]
Firm Profile (Form ADV)
Discretionary AUM$0.2B
ServesInstitutional
Fund TypesHedge Fund
LEI549300307G5AWN6LYD87
Comparable Firms State AUM
Engine Capital Management LP
NY 1,725.5 M
RK Capital Management LLC
FL 1,719.0 M
Broadwood Capital Inc
NY 1,711.4 M
North Peak Capital Management LLC
NY 1,703.0 M
Prescott General Partners LLC
FL 1,694.9 M
Parsifal Capital Management LP
CT 1,694.4 M
ADAR1 Capital Management LLC
TX 1,675.1 M
Quantitative Investment Management LLC
VA 1,670.6 M
FORA Capital LLC
FL 1,665.4 M
Philosophy Capital Management LLC
CA 1,663.1 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com